GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ayala Pharmaceuticals Inc (OTCPK:ADXS) » Definitions » Effective Interest Rate on Debt %

ADXS (Ayala Pharmaceuticals) Effective Interest Rate on Debt % : 1,070.87% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Ayala Pharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Ayala Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $63.16 Mil. Ayala Pharmaceuticals's average total debt for the quarter that ended in Dec. 2023 was $5.90 Mil. Therefore, Ayala Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 1,070.87%.


Ayala Pharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for Ayala Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ayala Pharmaceuticals Effective Interest Rate on Debt % Chart

Ayala Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial - - 49.52 - 312.82

Ayala Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 20.89 22.78 1,070.87

Competitive Comparison of Ayala Pharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Ayala Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ayala Pharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ayala Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Ayala Pharmaceuticals's Effective Interest Rate on Debt % falls into.



Ayala Pharmaceuticals Effective Interest Rate on Debt % Calculation

Ayala Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -15.746/( (1.751+8.316)/ 2 )
=-1  *  -15.746/5.0335
=312.82 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.332 + 0.419
=1.751

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=8.15 + 0.166
=8.316

Ayala Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  -63.16/( (3.48+8.316)/ 2 )
=-1  *  -63.16/5.898
=1,070.87 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=8.15 + 0.166
=8.316

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Ayala Pharmaceuticals  (OTCPK:ADXS) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Ayala Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Ayala Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ayala Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 08852
Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.
Executives
Yair Chaim Schindel other: shareholder of 10% holder YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
Roni Mamluk director, officer: CEO CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
Gary B. Gordon officer: Chief Medical Officer C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Vered Bisker-leib director C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Harel Insurance Co Ltd 10 percent owner ABBA HILLEL 3, RAMAT GAN L3 5211802
Amoon Growth Fund Limited Partnership 10 percent owner 34 YERUSHALAYIM RD., RAANANA L3 4350110
Murray A Goldberg director 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Maimon Yossi officer: CFO C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Harel Insurance Investments & Financial Services Ltd. 10 percent owner HAREL HOUSE, 3 ABBA HILLEL ST., RAMAT GAN L3 52118
Todd Sone director C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104